NCT07362836 2026-01-23
Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)
Fudan University
Phase 3 Not yet recruiting
Clinical Trials
10 trialsNCT07284394 2025-12-16
PACHA-02
UNICANCER
Phase 3 Not yet recruiting
NCT07271355 2025-12-09
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
Phase 3 Not yet recruiting
NCT06783491 2025-11-24
FOXHIPECT4
Maimónides Biomedical Research Institute of Córdoba
Phase 3 Not yet recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT06839092 2025-07-30
PROPAC
University Hospital, Geneva
Phase 3 Not yet recruiting
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06343116 2024-04-02
NOTABLE-308
Biotech Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT05699746 2023-01-26
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
Zhejiang University
Phase 3 Not yet recruiting
NCT05652894 2022-12-15
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Not yet recruiting